US6376549B1
(en)
*
|
1998-09-17 |
2002-04-23 |
Akesis Pharmaceuticals, Inc. |
Metforimin-containing compositions for the treatment of diabetes
|
US6852760B1
(en)
*
|
1998-09-17 |
2005-02-08 |
Akesis Pharmaceuticals, Inc. |
Compositions and methods for treatment for glucose metabolism disorders
|
DE19940130A1
(en)
*
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
New effectors of Dipeptidyl Peptidase IV for topical use
|
US20040152745A1
(en)
*
|
1999-11-12 |
2004-08-05 |
Guilford Pharmaceuticals, Inc. |
Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
|
AU1916401A
(en)
*
|
1999-11-12 |
2001-06-06 |
Guilford Pharmaceuticals Inc. |
Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
|
GB9928330D0
(en)
*
|
1999-11-30 |
2000-01-26 |
Ferring Bv |
Novel antidiabetic agents
|
CA2393083C
(en)
*
|
1999-12-23 |
2010-01-26 |
Novartis Ag |
Use of hypoglycemic agent for treating impaired glucose metabolism
|
US6380398B2
(en)
|
2000-01-04 |
2002-04-30 |
Novo Nordisk A/S |
Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
EP1248604B2
(en)
*
|
2000-01-21 |
2012-02-29 |
Novartis AG |
Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
|
US20080076811A1
(en)
*
|
2000-01-21 |
2008-03-27 |
Bork Balkan |
Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
|
JP2003520849A
(en)
*
|
2000-01-24 |
2003-07-08 |
ノボ ノルディスク アクティーゼルスカブ |
N-substituted 2-cyanopyrroles and -pyrrolines which are inhibitors of the enzyme DPP-IV
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US6432969B1
(en)
|
2000-06-13 |
2002-08-13 |
Novartis Ag |
N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
|
HUP0301622A3
(en)
|
2000-07-04 |
2006-05-29 |
Novo Nordisk As |
Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
|
PE20020617A1
(en)
*
|
2000-08-22 |
2002-08-05 |
Novartis Ag |
COMPOSITION INCLUDING AN AT1 RECEPTOR ANTAGONIST AND AN INSULIN SECRETION POTENTIAL OR AN INSULIN SENSITIZER
|
US20060089389A1
(en)
|
2000-08-22 |
2006-04-27 |
Malcolm Allison |
Combination
|
US20080249016A1
(en)
*
|
2000-09-18 |
2008-10-09 |
Sanos Bioscience A/S |
Use of GLP-2 in a combination treatment for bone-related disorders
|
US7371721B2
(en)
*
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
US20070135345A1
(en)
*
|
2000-09-18 |
2007-06-14 |
Henriksen Dennis B |
Use of GLP-2 for the treatment or prevention, of bone-related disorders
|
JP5161412B2
(en)
|
2000-09-18 |
2013-03-13 |
サノス・バイオサイエンス・アクティーゼルスカブ |
Methods of using GLP-1 and GLP-2 peptides
|
NZ525630A
(en)
|
2000-10-06 |
2004-10-29 |
Tanabe Seiyaku Co |
Nitrogen-containing 5-membered ring compound used as dipeptidylpeptidase IV (DPPIV) inhibitor
|
UA74023C2
(en)
*
|
2000-11-10 |
2005-10-17 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
TWI243162B
(en)
*
|
2000-11-10 |
2005-11-11 |
Taisho Pharmaceutical Co Ltd |
Cyanopyrrolidine derivatives
|
US20040180925A1
(en)
*
|
2000-12-27 |
2004-09-16 |
Kenji Matsuno |
Dipeptidylpeptidase-IV inhibitor
|
GB0109146D0
(en)
*
|
2001-04-11 |
2001-05-30 |
Ferring Bv |
Treatment of type 2 diabetes
|
US20030060494A1
(en)
*
|
2001-05-18 |
2003-03-27 |
Nobuyuki Yasuda |
Pharmaceutical use of N-carbamoylazole derivatives
|
CA2450579A1
(en)
|
2001-06-20 |
2003-01-03 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
EP1406622B1
(en)
|
2001-06-20 |
2006-02-22 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
CN1990468A
(en)
|
2001-06-27 |
2007-07-04 |
史密丝克莱恩比彻姆公司 |
Pyrrolidines as dipeptidyl peptidase inhibitors
|
WO2003002530A2
(en)
*
|
2001-06-27 |
2003-01-09 |
Smithkline Beecham Corporation |
Pyrrolidines as dipeptidyl peptidase inhibitors
|
US7183290B2
(en)
*
|
2001-06-27 |
2007-02-27 |
Smithkline Beecham Corporation |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
US6709651B2
(en)
*
|
2001-07-03 |
2004-03-23 |
B.M.R.A. Corporation B.V. |
Treatment of substance P-related disorders
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
EP1470246A2
(en)
*
|
2001-10-31 |
2004-10-27 |
Novartis AG |
Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
|
US20050101638A1
(en)
*
|
2002-11-08 |
2005-05-12 |
Webb Randy L. |
Combination of organic compounds
|
US20030135663A1
(en)
*
|
2002-01-16 |
2003-07-17 |
Sun Microsystems, Inc. |
Method, system, and program for including device parameters from a device driver in a configuration file
|
JP4359146B2
(en)
|
2002-02-13 |
2009-11-04 |
エフ.ホフマン−ラ ロシュ アーゲー |
Novel pyridine- and pyrimidine-derivatives
|
RU2285693C2
(en)
|
2002-02-13 |
2006-10-20 |
Ф.Хоффманн-Ля Рош Аг |
Derivatives of pyridine and quinoline, method for their preparing, pharmaceutical composition, using compounds for treatment of dpp-iv-associated diseases
|
EP1338595B1
(en)
|
2002-02-25 |
2006-05-03 |
Eisai Co., Ltd. |
Xanthine derivatives as DPP-IV inhibitors
|
DE60316416T2
(en)
*
|
2002-03-25 |
2008-06-26 |
Merck & Co., Inc. |
HETEROCYCLIC BETA-AMINO COMPOUNDS AS INHIBITORS OF DIPEPTIDYLPEPTIDASE FOR TREATMENT OR PREVENTION OF DIABETES
|
ES2321600T3
(en)
*
|
2002-06-03 |
2009-06-09 |
Novartis Ag |
THE USE OF SUBSTITUTED CYANOPIRROLIDINS TO TREAT HYPERLIPIDEMIA.
|
US6710040B1
(en)
*
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
JP2004026678A
(en)
*
|
2002-06-24 |
2004-01-29 |
Microbial Chem Res Found |
Therapeutic agent for type 2 diabetes
|
AU2003248259A1
(en)
*
|
2002-07-10 |
2004-02-02 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel azetidine derivative or salt thereof
|
DE60330485D1
(en)
*
|
2002-07-15 |
2010-01-21 |
Merck & Co Inc |
FOR THE TREATMENT OF DIABETES
|
TW200401635A
(en)
*
|
2002-07-23 |
2004-02-01 |
Yamanouchi Pharma Co Ltd |
2-Cyano-4-fluoropyrrolidine derivative or salt thereof
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
WO2004026822A2
(en)
*
|
2002-09-19 |
2004-04-01 |
Abbott Laboratories |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
|
WO2004032836A2
(en)
*
|
2002-10-07 |
2004-04-22 |
Merck & Co., Inc. |
Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors
|
RU2301803C2
(en)
|
2002-10-18 |
2007-06-27 |
Мерк Энд Ко., Инк. |
Derivatives of hexahydrodiazepinone, pharmaceutical composition containing thereof and using in preparing medicinal agent for treatment of non-insulin dependent diabetes mellitus
|
AU2003290577B2
(en)
|
2002-11-07 |
2008-12-11 |
Merck Sharp & Dohme Corp. |
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
WO2004050022A2
(en)
*
|
2002-12-04 |
2004-06-17 |
Merck & Co., Inc. |
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
AU2003297219A1
(en)
*
|
2002-12-20 |
2004-07-22 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
AU2004205642C1
(en)
|
2003-01-14 |
2012-01-12 |
Arena Pharmaceuticals, Inc. |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
EP1589969A4
(en)
|
2003-01-17 |
2008-08-13 |
Merck & Co Inc |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US7388019B2
(en)
*
|
2003-01-31 |
2008-06-17 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US20040242568A1
(en)
|
2003-03-25 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
PE20081293A1
(en)
*
|
2003-04-16 |
2008-11-04 |
Novartis Ag |
PROCEDURE FOR THE PREPARATION OF COMPOUNDS 2 (S) -CYANOPYRROLIDINE N- (SUBSTITUTE N'-GLYCYL)
|
GB0308854D0
(en)
*
|
2003-04-16 |
2003-05-21 |
Novartis Ag |
Organic compounds
|
EP1625122A1
(en)
|
2003-05-14 |
2006-02-15 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
CN1787823A
(en)
|
2003-05-14 |
2006-06-14 |
麦克公司 |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
JP2006527194A
(en)
|
2003-06-06 |
2006-11-30 |
メルク エンド カムパニー インコーポレーテッド |
Condensed indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
AU2004249163A1
(en)
*
|
2003-06-17 |
2004-12-29 |
Merck & Co., Inc. |
Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
CN101090901B
(en)
|
2003-06-20 |
2010-12-15 |
霍夫曼-拉罗奇有限公司 |
Hexahydropyridoisoqinolines as DPP-IV inhibitors
|
DE602004030244D1
(en)
|
2003-06-20 |
2011-01-05 |
Hoffmann La Roche |
ITOREN
|
US7259160B2
(en)
|
2003-07-31 |
2007-08-21 |
Merck & Co., Inc. |
Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
BRPI0413452A
(en)
|
2003-08-13 |
2006-10-17 |
Takeda Pharmaceutical |
compound, pharmaceutical composition, kit, article of manufacture, and methods of inhibiting dpp-iv, therapeutic, and treating a disease state, cancer, autoimmune disorders, a condition and HIV infection
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2005026148A1
(en)
|
2003-09-08 |
2005-03-24 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
PE20050948A1
(en)
*
|
2003-09-09 |
2005-12-16 |
Japan Tobacco Inc |
CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
|
WO2005033099A2
(en)
*
|
2003-10-03 |
2005-04-14 |
Glenmark Pharmaceuticals Ltd. |
Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
|
WO2005049027A2
(en)
*
|
2003-11-03 |
2005-06-02 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
AU2004286857A1
(en)
*
|
2003-11-04 |
2005-05-19 |
Merck & Co., Inc. |
Fused phenylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
KR20070054762A
(en)
*
|
2003-11-12 |
2007-05-29 |
페노믹스 코포레이션 |
Heterocyclic boronic acid compounds
|
KR20060109911A
(en)
*
|
2003-11-17 |
2006-10-23 |
노파르티스 아게 |
Use of dipeptidyl peptidase iv inhibitors
|
EP1715893B8
(en)
|
2004-01-20 |
2009-12-16 |
Novartis Ag |
Direct compression formulation and process
|
PL1712547T3
(en)
*
|
2004-02-05 |
2012-04-30 |
Kyorin Seiyaku Kk |
Bicycloester derivative
|
JPWO2005077900A1
(en)
*
|
2004-02-18 |
2007-10-18 |
杏林製薬株式会社 |
Bicycloamide derivatives
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
AU2005215136A1
(en)
*
|
2004-02-20 |
2005-09-01 |
Novartis Ag |
DPP-IV inhibitors for treating neurodegeneration and cognitive disorders
|
EP1719757B1
(en)
*
|
2004-02-27 |
2013-10-09 |
Kyorin Pharmaceutical Co., Ltd. |
Bicyclo derivative
|
WO2005087235A1
(en)
*
|
2004-03-09 |
2005-09-22 |
National Health Research Institutes |
Pyrrolidine compounds
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN102134231B
(en)
|
2004-03-15 |
2020-08-04 |
武田药品工业株式会社 |
Dipeptidyl peptidase inhibitors
|
TW200604167A
(en)
*
|
2004-04-27 |
2006-02-01 |
Astellas Pharma Inc |
Pyrrolidine derivatives
|
WO2005108382A1
(en)
*
|
2004-05-04 |
2005-11-17 |
Merck & Co., Inc. |
1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
CN1960990A
(en)
|
2004-05-18 |
2007-05-09 |
默克公司 |
Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US7935723B2
(en)
*
|
2004-06-04 |
2011-05-03 |
Novartis Pharma Ag |
Use of organic compounds
|
WO2005118555A1
(en)
|
2004-06-04 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CA2573848A1
(en)
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Constrained cyano compounds
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
ATE553077T1
(en)
*
|
2004-07-23 |
2012-04-15 |
Nuada Llc |
PEPTIDATE INHIBITORS
|
TW200608967A
(en)
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
PE20060652A1
(en)
*
|
2004-08-27 |
2006-08-11 |
Novartis Ag |
IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS INCLUDING FUSION GRANULES
|
AP2007003973A0
(en)
|
2004-10-12 |
2007-07-30 |
Glenmark Pharmaceuticals Sa |
Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
|
WO2006047248A1
(en)
*
|
2004-10-25 |
2006-05-04 |
Novartis Ag |
Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
|
DE102004054054A1
(en)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
|
MX2007007434A
(en)
|
2004-12-20 |
2007-07-17 |
Hoffmann La Roche |
4-aminopiperidine derivatives.
|
US7411093B2
(en)
|
2004-12-20 |
2008-08-12 |
Hoffman-La Roche Inc. |
Aminocycloalkanes as DPP-IV inhibitors
|
JP2008524331A
(en)
|
2004-12-21 |
2008-07-10 |
武田薬品工業株式会社 |
Dipeptidyl peptidase inhibitor
|
DOP2006000008A
(en)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
|
GT200600008A
(en)
*
|
2005-01-18 |
2006-08-09 |
|
FORMULATION OF DIRECT COMPRESSION AND PROCESS
|
JP2008024592A
(en)
*
|
2005-01-28 |
2008-02-07 |
Taisho Pharmaceut Co Ltd |
Cyanopyrrolidine derivative-containing composition for solid preparation, solid preparation containing the composition and process for producing the solid preparation
|
WO2006090244A1
(en)
*
|
2005-02-22 |
2006-08-31 |
Glenmark Pharmaceuticals S.A. |
New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them
|
TWI357902B
(en)
|
2005-04-01 |
2012-02-11 |
Lg Life Science Ltd |
Dipeptidyl peptidase-iv inhibiting compounds, meth
|
ZA200708179B
(en)
|
2005-04-22 |
2009-12-30 |
Alantos Pharmaceuticals Holding Inc |
Dipeptidyl peptidase-IV inhibitors
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
CA2610022A1
(en)
|
2005-06-06 |
2006-12-14 |
Georgetown University |
Compositions and methods for lipo modeling
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
EP1912706A4
(en)
*
|
2005-06-17 |
2009-05-27 |
Aurigene Discovery Technologie |
Novel 5-substituted indole derivatives as dipeptidyl peptidase iv (dpp-iv) inhibitors
|
AU2006268650A1
(en)
*
|
2005-07-12 |
2007-01-18 |
Novartis Ag |
Combination of a DPP-IV inhibitor and a cannabinoid CB1 receptor antagonist
|
DE102005035891A1
(en)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
|
US20080279932A1
(en)
*
|
2005-08-04 |
2008-11-13 |
Jean-Louis Reber |
Compounds
|
GT200600381A
(en)
|
2005-08-25 |
2007-03-28 |
|
ORGANIC COMPOUNDS
|
PL1942898T5
(en)
|
2005-09-14 |
2014-10-31 |
Takeda Pharmaceuticals Co |
Dipeptidyl peptidase inhibitors for treating diabetes
|
US8222411B2
(en)
|
2005-09-16 |
2012-07-17 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
JOP20180109A1
(en)
*
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
New Formulation
|
AU2006301892A1
(en)
*
|
2005-10-07 |
2007-04-19 |
Waratah Pharmaceuticals, Inc. |
Combined use of DPP IV inhibitors and gastrin compounds
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
BRPI0706423A2
(en)
*
|
2006-01-06 |
2011-03-29 |
Novartis Ag |
use of organic compounds
|
EP1995237A4
(en)
|
2006-03-08 |
2011-07-06 |
Kyorin Seiyaku Kk |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
|
AU2007227202B2
(en)
|
2006-03-21 |
2013-08-22 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase inhibitor conjugates and methods of using same
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
BRPI0709894A2
(en)
*
|
2006-04-03 |
2011-07-26 |
Matrix Lab Ltd |
dipeptidyl peptidase iv inhibitors and processes for their preparation and pharmaceutical composition containing them
|
MX2008012756A
(en)
*
|
2006-04-03 |
2009-03-05 |
Matrix Lab Ltd |
Novel dipeptidyl peptidase iv inhibitors and processes for their preparation and pharmaceutical compositions containing them.
|
EP2402750A1
(en)
|
2006-04-11 |
2012-01-04 |
Arena Pharmaceuticals, Inc. |
Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
|
PE20071221A1
(en)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
|
BRPI0711558A2
(en)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polymorphs
|
PE20080251A1
(en)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
USES OF DPP IV INHIBITORS
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
EA200870575A1
(en)
|
2006-05-26 |
2009-08-28 |
Амилин Фармасьютикалз, Инк. |
COMPOSITIONS AND METHODS OF TREATMENT OF CONSTITUAL HEART FAILURE
|
NZ574710A
(en)
|
2006-09-07 |
2012-02-24 |
Nycomed Gmbh |
Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
|
DK2073810T3
(en)
*
|
2006-09-13 |
2011-10-31 |
Takeda Pharmaceutical |
Use of 2-6- (3-amino-piperidin-1-yl) -3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile in the treatment of diabetes, cancer, autoimmune diseases and HIV infection
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
WO2008084383A2
(en)
*
|
2007-01-10 |
2008-07-17 |
Medichem, S.A. |
Process for preparing vildagliptin
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
JPWO2008114857A1
(en)
|
2007-03-22 |
2010-07-08 |
杏林製薬株式会社 |
Process for producing aminoacetylpyrrolidinecarbonitrile derivative
|
KR101361427B1
(en)
|
2007-04-03 |
2014-02-10 |
미쓰비시 타나베 파마 코퍼레이션 |
Combined use of dipeptidyl peptidase iv inhibitor compound and sweetener
|
DE102007022007A1
(en)
*
|
2007-05-08 |
2008-11-13 |
Schebo Biotech Ag |
Novel pharmaceuticals, process for their preparation and their use in the prophylaxis and therapy of CNS diseases and diabetes
|
AU2008259342B2
(en)
|
2007-06-04 |
2014-07-10 |
Ben-Gurion University Of The Negev Research And Development Authority |
Tri-aryl compounds and compositions comprising the same
|
PE20090938A1
(en)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL
|
RU2569749C2
(en)
*
|
2007-08-17 |
2015-11-27 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Purine derivatives applicable for treating fap-related (fibroblast activator protein) diseases
|
WO2009037719A1
(en)
*
|
2007-09-21 |
2009-03-26 |
Lupin Limited |
Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
|
US20090082420A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched vildagliptin
|
US8598314B2
(en)
*
|
2007-09-27 |
2013-12-03 |
Amylin Pharmaceuticals, Llc |
Peptide-peptidase-inhibitor conjugates and methods of making and using same
|
RU2489439C2
(en)
*
|
2007-11-30 |
2013-08-10 |
Новартис Аг |
Organic compounds
|
CN101945851B
(en)
|
2007-12-12 |
2012-10-31 |
阿斯利康(瑞典)有限公司 |
Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
|
US8470836B2
(en)
|
2007-12-21 |
2013-06-25 |
Lg Life Sciences, Ltd. |
Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
|
CL2008003653A1
(en)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
|
US8551524B2
(en)
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
AR071175A1
(en)
*
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
|
EP2108960A1
(en)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
|
PE20100156A1
(en)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
NAFLD TREATMENT
|
WO2009155309A1
(en)
*
|
2008-06-19 |
2009-12-23 |
Concert Pharmaceuticals, Inc. |
Substituted cyanopyrrolidine derivatives
|
UY32030A
(en)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
|
KR20190016601A
(en)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment for diabetes in patients inappropriate for metformin therapy
|
CA2732984A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Kyorin Pharmaceutical Co., Ltd. |
Process for production of bicyclo[2.2.2]octylamine derivative
|
RU2011108420A
(en)
*
|
2008-08-14 |
2012-09-20 |
Киорин Фармасьютикал Ко., Лтд. (Jp) |
STABILIZED PHARMACEUTICAL COMPOSITION
|
AU2009281122C1
(en)
*
|
2008-08-15 |
2016-04-21 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
CZ2008512A3
(en)
*
|
2008-08-26 |
2010-03-10 |
Zentiva, A. S |
Process for preparing extremely pure vildagliptin
|
EP2344195A2
(en)
|
2008-09-10 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Combination therapy for the treatment of diabetes and related conditions
|
CN102850330B
(en)
*
|
2008-09-23 |
2014-10-15 |
成都地奥制药集团有限公司 |
Method for preparing N-substituted pyrrolidine derivative through bromination
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
JP2012512848A
(en)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Salt forms of organic compounds
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
US8466145B2
(en)
|
2009-01-09 |
2013-06-18 |
Orchid Chemicals & Pharmaceuticals Limited |
Dipeptidyl peptidase IV inhibitors
|
AR075204A1
(en)
|
2009-01-29 |
2011-03-16 |
Boehringer Ingelheim Int |
DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2
|
ES2797503T3
(en)
|
2009-02-13 |
2020-12-02 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising an SGLT2 inhibitor, a DPP-IV inhibitor and optionally an additional antidiabetic agent and their uses
|
JP2012517977A
(en)
|
2009-02-13 |
2012-08-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
An anti-diabetic drug comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other anti-diabetic drugs
|
KR20120003906A
(en)
|
2009-03-27 |
2012-01-11 |
교린 세이야꾸 가부시키 가이샤 |
Matrix-type sustained release preparation containing basic additive
|
AU2010244218B2
(en)
|
2009-05-07 |
2012-07-19 |
Astrazeneca Ab |
Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
|
MX2011012198A
(en)
|
2009-05-15 |
2011-12-08 |
Novartis Ag |
Aryl pyridine as aldosterone synthase inhibitors.
|
JP5654572B2
(en)
|
2009-05-15 |
2015-01-14 |
ノバルティス アーゲー |
Benzoxazolone derivatives as aldosterone synthase inhibitors
|
BRPI1011657A2
(en)
|
2009-05-28 |
2019-04-16 |
Novartis Ag |
substituted aminopropionic derivatives as neprilysin inhibitors
|
SG176010A1
(en)
|
2009-05-28 |
2011-12-29 |
Novartis Ag |
Substituted aminobutyric derivatives as neprilysin inhibitors
|
US8748457B2
(en)
|
2009-06-18 |
2014-06-10 |
Lupin Limited |
2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
|
AR077642A1
(en)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
EA034049B1
(en)
*
|
2009-07-31 |
2019-12-23 |
КРКА, д.д., НОВО МЕСТО |
Granulate comprising vildagliptin, process of preparation thereof and pharmaceutical composition
|
WO2011028455A1
(en)
|
2009-09-02 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
JP5696856B2
(en)
|
2009-09-03 |
2015-04-08 |
バイオエナジェニックス |
Heterocyclic compounds for inhibition of PASK
|
EA201200486A1
(en)
|
2009-09-15 |
2012-08-30 |
Серулин Фарма Инк. |
TREATMENT OF ONCOLOGICAL DISEASES
|
EP2295083A1
(en)
|
2009-09-15 |
2011-03-16 |
Ratiopharm GmbH |
Pharmaceutical composition comprising active agents metformin and sitagliptin or vildagliptin
|
HUP0900638A2
(en)
|
2009-10-07 |
2011-05-30 |
Egyt Gyogyszervegyeszeti Gyar |
Adducts of inorganic salts basea on vildaelitpin applicable for preparation of pharmaceutical compositions
|
EP2308847B1
(en)
|
2009-10-09 |
2014-04-02 |
EMC microcollections GmbH |
Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
|
AU2010303780B2
(en)
|
2009-10-09 |
2014-02-20 |
Irm Llc |
Compounds and compositions as modulators of GPR119 activity
|
ES2663351T3
(en)
|
2009-11-17 |
2018-04-12 |
Novartis Ag |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
|
CN102781237A
(en)
|
2009-11-23 |
2012-11-14 |
天蓝制药公司 |
Cyclodextrin-based polymers for therapeutic delivery
|
KR20210033559A
(en)
|
2009-11-27 |
2021-03-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
US8575160B2
(en)
|
2009-11-30 |
2013-11-05 |
Novartis Ag |
Imidazole derivatives as aldosterone synthase inhibitors
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
JP5686413B2
(en)
|
2009-12-22 |
2015-03-18 |
塩野義製薬株式会社 |
Adamantanamine derivative
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
US8853212B2
(en)
|
2010-02-22 |
2014-10-07 |
Merck Sharp & Dohme Corp |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
|
CN101798270B
(en)
*
|
2010-02-25 |
2013-04-17 |
东华大学 |
Method for preparing 3-amino-1-adamantane alcohol
|
EP2547339A1
(en)
|
2010-03-18 |
2013-01-23 |
Boehringer Ingelheim International GmbH |
Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
WO2011127051A1
(en)
|
2010-04-06 |
2011-10-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US9186392B2
(en)
|
2010-05-05 |
2015-11-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
EP2571876B1
(en)
|
2010-05-21 |
2016-09-07 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
CN102260265B
(en)
|
2010-05-24 |
2015-09-02 |
上海阳帆医药科技有限公司 |
Hexahydropyrrolo [3,4-b] pyrrole derivative, Its Preparation Method And Use
|
CN101870671B
(en)
*
|
2010-06-11 |
2012-06-27 |
漆又毛 |
Adamantly pyrrolidine derivative, and preparation and application thereof
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
IT1400714B1
(en)
|
2010-07-06 |
2013-06-28 |
Chemelectiva S R L |
PROCESS AND INTERMEDIATE FOR THE PREPARATION OF AN ACTIVE PRINCIPLE.
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
KR101519280B1
(en)
|
2010-08-09 |
2015-05-11 |
시오노기세이야쿠가부시키가이샤 |
Process for preparing aminoadamantyl carbamate derivatives
|
HU231050B1
(en)
|
2010-08-19 |
2020-02-28 |
Egis Gyógyszergyár Nyrt. |
Process for the preparation of a pharmaceutical active ingredient
|
AU2011305525B2
(en)
|
2010-09-22 |
2016-08-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
AR083878A1
(en)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
TR201107482A1
(en)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç San.Ve Ti̇c.A.Ş. |
The bilayer combination composition of vildagliptin and glyclazide.
|
TR201010683A1
(en)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç San. Ve Ti̇c. A.Ş. |
Vildagliptin formulations.
|
TR201101809A1
(en)
|
2010-12-21 |
2012-07-23 |
Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ |
Vildagliptin and glimepiride combinations.
|
EP2468268B1
(en)
|
2010-12-21 |
2017-12-13 |
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi |
Combination composition of vildagliptin and gliclazide
|
US10017470B2
(en)
|
2011-01-31 |
2018-07-10 |
Cadila Healthcare Limited |
Treatment for lipodystrophy
|
CN103459382B
(en)
|
2011-03-02 |
2016-06-29 |
拜奥埃内杰尼克斯公司 |
For suppressing the heterocyclic compound of PASK
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
EP2729468A4
(en)
|
2011-07-05 |
2015-03-18 |
Merck Sharp & Dohme |
Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
|
CA2841552C
(en)
|
2011-07-15 |
2020-06-23 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
EP2753328A1
(en)
|
2011-09-07 |
2014-07-16 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dpp-iv inhibitor formulations
|
EP2572704A1
(en)
|
2011-09-22 |
2013-03-27 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Orally-Disintegrating Formulations of Vildagliptin
|
PL2578208T3
(en)
|
2011-10-06 |
2014-10-31 |
Sanovel Ilac Sanayi Ve Ticaret As |
DPP-IV inhibitor solid dosage formulations
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
ITMI20112224A1
(en)
|
2011-12-06 |
2013-06-07 |
Chemelectiva S R L |
NEW PROCESS AND INTERMEDIATE FOR THE SYNTHESIS OF VILDAGLIPTIN
|
CN102491928A
(en)
*
|
2011-12-13 |
2012-06-13 |
临海天宇药业有限公司 |
Method for preparing (2S)-N-chloracetyl-2-cyano-group pyrrolidine
|
US9115082B2
(en)
|
2012-01-18 |
2015-08-25 |
Catherine Yang |
Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
|
EP2814485A4
(en)
|
2012-02-17 |
2015-08-26 |
Merck Sharp & Dohme |
Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
CN102617434B
(en)
*
|
2012-03-29 |
2014-07-23 |
中国科学院上海有机化学研究所 |
Process for preparing Vildagliptin by one-pot method
|
WO2013179300A2
(en)
|
2012-05-04 |
2013-12-05 |
Megafine Pharma (P) Ltd. |
A process for the preparation of vildagliptin and its intermediate thereof
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2014018350A1
(en)
|
2012-07-23 |
2014-01-30 |
Merck Sharp & Dohme Corp. |
Treating diabetes with dipeptidyl peptidase-iv inhibitors
|
WO2014020462A1
(en)
*
|
2012-08-01 |
2014-02-06 |
Alembic Pharmaceuticals Limited |
Improved process for preparation of vildagliptin intermediate
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
TWI500613B
(en)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
Novel heterocyclic compounds
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
UY35144A
(en)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
|
CN103922986B
(en)
*
|
2013-01-16 |
2017-02-15 |
上海彩迩文生化科技有限公司 |
Vildagliptin, vildagliptin analogues and vildagliptin intermediate, and preparation methods of three and application
|
CN105073762B
(en)
|
2013-02-14 |
2017-03-08 |
诺华股份有限公司 |
Substituted biphenyl butyryl phosphonate derivative as NEP (neutral endopeptidase) inhibitor
|
MA38385A1
(en)
|
2013-04-22 |
2017-09-29 |
Cadila Healthcare Ltd |
New composition for non-alcoholic fatty liver disease (nafld)
|
EP3004053B1
(en)
|
2013-05-30 |
2021-03-24 |
Cadila Healthcare Limited |
A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
|
CN103304502B
(en)
*
|
2013-06-02 |
2015-03-04 |
张远强 |
Anti-diabetic compound, as well as preparation method and application thereof
|
TW201513857A
(en)
|
2013-07-05 |
2015-04-16 |
Cadila Healthcare Ltd |
Synergistic compositions
|
MX2016001020A
(en)
|
2013-07-25 |
2016-08-03 |
Novartis Ag |
Cyclic polypeptides for the treatment of heart failure.
|
KR20160031552A
(en)
|
2013-07-25 |
2016-03-22 |
노파르티스 아게 |
Bioconjugates of synthetic apelin polypeptides
|
IN2013MU02470A
(en)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
IN2013MU02905A
(en)
|
2013-09-06 |
2015-07-03 |
Cadila Healthcare Ltd |
|
CN106061940A
(en)
|
2013-11-05 |
2016-10-26 |
本古里安大学内盖夫研究发展局 |
Compounds for the treatment of diabetes and disease complications arising from same
|
CN103641761A
(en)
*
|
2013-11-22 |
2014-03-19 |
沈阳化工大学 |
Vildagliptin preparation method
|
ES2950384T3
(en)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Medical use of a DPP-4 inhibitor
|
WO2015132359A1
(en)
|
2014-03-06 |
2015-09-11 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Vildagliptin formulation process under inert gas atmosphere
|
CN103992257B
(en)
*
|
2014-05-16 |
2016-03-30 |
苏州天马精细化学品股份有限公司 |
A kind of purification process of Vildagliptin crude product
|
CN105439873A
(en)
*
|
2014-08-20 |
2016-03-30 |
天津药物研究院 |
3-hydroxy-1-amantadine preparation method
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
CN105884669B
(en)
*
|
2014-09-15 |
2020-05-15 |
深圳翰宇药业股份有限公司 |
Process for the preparation of substituted (S) -pyrrolidine-2-carbonitriles and vildagliptin
|
AU2016205361C1
(en)
|
2015-01-06 |
2021-04-08 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
CN104529857B
(en)
*
|
2015-01-13 |
2016-03-30 |
佛山市赛维斯医药科技有限公司 |
Halo diamantane amide derivatives, Preparation Method And The Use
|
MA41580A
(en)
|
2015-01-23 |
2017-11-29 |
Novartis Ag |
SYNTHETIC APELIN FATTY ACID CONJUGATES WITH IMPROVED HALF-LIFE
|
EA201791982A1
(en)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
METHODS FOR TREATING A NON-ALCOHOLIC FAT LIVER DISEASE AND / OR LIPODYSTROPHY
|
CN104761456B
(en)
*
|
2015-03-10 |
2020-04-10 |
上海威智医药科技有限公司 |
Preparation method of 3-amino-1-adamantanol
|
CN104817482B
(en)
*
|
2015-03-17 |
2017-05-10 |
宁波百思佳医药科技有限公司 |
2-substituted pyrrolidine compound, preparation method and application thereof in preparation of vildagliptin
|
BR112017027656B1
(en)
|
2015-06-22 |
2023-12-05 |
Arena Pharmaceuticals, Inc. |
CRYSTALLINE HABIT OF SALT-FREE PLATE OF ACID L-ARGININE (R)-2-(7-(4- CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)- 1,2,3,4-TETRA-HYDROCYCLO-PENTA[B ]INDOL-3- IL)ACETIC, PHARMACEUTICAL COMPOSITION THAT COMPRISES IT, ITS USES AND METHOD OF PREPARATION THEREOF
|
WO2017064635A2
(en)
|
2015-10-14 |
2017-04-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
RU2628573C2
(en)
*
|
2015-11-27 |
2017-08-21 |
Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" |
Dipeptidyl peptidase-4 inhibitor for treatment of type 2 diabetes
|
MX2018007681A
(en)
|
2015-12-28 |
2018-11-14 |
Wockhardt Ltd |
An oral osmotic pharmaceutical composition of vildagliptin.
|
CA3022202A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
DE102016116130A1
(en)
|
2016-08-30 |
2018-03-01 |
Universität Bielefeld |
Process for the preparation of chiral aminonitriles
|
PL3512505T3
(en)
|
2016-09-16 |
2023-08-07 |
Galenicum Health S.L.U. |
Vildagliptin pharmaceutical compositions
|
JOP20190086A1
(en)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
Naphthyridinone derivatives and their use in the treatment of arrhythmia
|
WO2018104916A1
(en)
|
2016-12-09 |
2018-06-14 |
Cadila Healthcare Limited |
Treatment for primary biliary cholangitis
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
CA3058806A1
(en)
|
2017-04-03 |
2018-10-11 |
Coherus Biosciences Inc. |
Ppar.gamma. agonist for treatment of progressive supranuclear palsy
|
GR1009406B
(en)
|
2017-10-03 |
2018-11-26 |
Φαρματεν Αβεε |
Pharmaceutical composition comprising vildagliptin and method of preparation thereof
|
UY38072A
(en)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
|
KR102622198B1
(en)
|
2018-03-30 |
2024-01-09 |
한미약품 주식회사 |
Solid formulation for oral administration containing vildagliptin and a process for the preparation thereof
|
GR1009644B
(en)
|
2018-09-25 |
2019-11-12 |
Φαρματεν Α.Β.Ε.Ε. |
Pharmaceutical composition comprising vildagliptin and metformin and method of preparation thereof
|
UY38485A
(en)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION
|
WO2020110008A1
(en)
|
2018-11-27 |
2020-06-04 |
Novartis Ag |
Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
|
CN113166204A
(en)
|
2018-11-27 |
2021-07-23 |
诺华股份有限公司 |
Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
|
JP7461735B2
(en)
*
|
2019-12-02 |
2024-04-04 |
日本ジェネリック株式会社 |
Vildagliptin-containing tablets
|
CN113527167B
(en)
*
|
2020-04-14 |
2024-01-19 |
威智医药股份有限公司 |
Production method of vildagliptin
|
WO2021234430A1
(en)
|
2020-05-17 |
2021-11-25 |
Lotus International Pte. Ltd. |
Modified release dosage form comprising vildagliptin and process for manufacturing the same
|
WO2022003405A1
(en)
|
2020-07-03 |
2022-01-06 |
Savoi Guilherme |
One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same
|
JP2023536346A
(en)
|
2020-08-05 |
2023-08-24 |
エリプシーズ ファーマ リミテッド |
Treatment of Cancer with Cyclodextrin-Containing Polymeric Topoisomerase Inhibitor Conjugates and PARP Inhibitors
|
AU2022211069A1
(en)
*
|
2021-01-21 |
2023-07-27 |
The Scripps Research Institute |
Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases
|
WO2023084449A1
(en)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
|
AR127698A1
(en)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
|